The biotechnology and pharmaceutical industry shows intensive progress, with Guotai Hang Seng Biotechnology ETF (520930) rising more than 2.3%

The pharmaceutical and biotech industry is showing rapid progress. On March 16, Hang Seng Biotech ETF Guotai (520930) closed up more than 2.3%.

Guosheng Securities pointed out that the industry has recently seen intensive developments. A milestone breakthrough has been achieved in the brain-computer interface field, as the National Medical Products Administration approved the launch of the world’s first invasive brain-computer interface medical device, marking the transition of this technology from exploration to clinical application, opening up commercial opportunities in neural regulation and implantable medical devices. In terms of innovative drugs, major national science and technology projects support the development of anti-Alzheimer’s medications, demonstrating a focus on central nervous system and other major diseases. Several companies have made progress in R&D, including collaborations on GLP-1 drugs, FDA approval for clinical trials of bispecific antibody ADCs, and clinical advancement of drugs for conditions such as heart attack and atopic dermatitis, showcasing the industry’s R&D execution capabilities.

The Hang Seng Biotech Index focuses on the “crown jewel” of innovative drugs, offering three major advantages: leading companies, scarce futures liquidity, and high elasticity & high Sharpe ratio. Investors seeking convenient access to core innovative drug leaders can consider the Hang Seng Biotech ETF Guotai (520933) for one-click deployment.

Risk reminder: Mentioned stocks are for industry event analysis only and do not constitute any stock recommendation or investment advice. Short-term index fluctuations are for reference only and do not predict future performance, nor do they constitute a promise or guarantee of fund performance. Views may change with market conditions and do not constitute investment advice or commitments. Different funds have different risk-return profiles; investors should carefully read the fund legal documents, fully understand product features, risk levels, and income distribution principles, and choose products that match their risk tolerance. Invest cautiously.

Daily Economic News

(Disclaimer: This article only reflects the author’s personal views and is not related to Hexun. Hexun website maintains neutrality regarding the statements and opinions in the article and does not provide any explicit or implicit guarantees on the accuracy, reliability, or completeness of the content. Readers are advised to use it for reference only and bear all responsibilities themselves. Email: news_center@staff.hexun.com)